Dharmais National Cancer Center
Jakarta, Jakarta Special Capital Region, 11420, Indonesia
Location status: Recruiting
NCT Number: NCT07233863
This study aims to evaluate the effectiveness of the Lymphovenous Bypass (LVB) procedure compared to physiotherapy alone as secondary prevention of lymphedema in breast cancer patients undergoing axillary lymph node dissection.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Jakarta, Jakarta Special Capital Region, 11420, Indonesia
Location status: Recruiting
In the intervention group, LVB was performed with intima-to-intima coaptation using the super microsurgery technique. The anastomosis was between the afferent lymphatic vessel and the recipient vein. The upper extremity lymphedema (UEL) index and indocyanine green (ICG) lymphography are utilized to evaluate the progression of lymphedema.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The Lymphovenous Bypass (LVB) procedure in this study is a microsurgical supermicrosurgery-based intervention specifically designed for the secondary prevention of breast cancer-related lymphedema following axillary lymph node dissection.
Time frame: 24 months
BCRL definition:
Post-operation subject condition with the presence of minimum DB 2 with one or both symptoms (swelling, heaviness), and an increment of UEL index >10% compared to pre-operation OR Post-operation subject condition with presence of ≥ DB 2 with minimum area 30% in one arm region in one of the arm lymphatic pathways (anterior or posterior), without presence of symptoms (swelling or heaviness), and increment of UEL index >10% compared to pre-operation.
International Society of Lymphology (ISL) stage 1 definition:
An early stage of lymphedema is characterized by soft tissue swelling that may subside with limb elevation or overnight rest, without permanent structural changes.
BCRL improvement :
Improvement in ICG lymphography stage with or without clinical signs (UEL <10% and or symptoms improvement)
Time frame: 24 months
QLQ-BR23 is a supplement to the EORTC QLQ-30, specific to breast cancer patients, containing 23 questions and scored from 0 (not at all) to 4 (very much). To evaluate the quality of life, we asked three questions about the arm (pain, swelling, and mobility issues). The quality of life decreases with a higher score.
Time frame: 24 months
Complications such as seroma, hematoma, wound separation, bleeding, and wound infection can be seen after surgery.
Contact information is provided by the study sponsor or research team.
Dharmais National Cancer Center Hospital
Other Gov
Effectiveness of Lymphovenous Bypass Procedure for Secondary Prevention of Lymphedema in Breast Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05142800
Breast Cancer, Breast Cancer Lymphedema
Boston, Massachusetts, United States
View Trial DetailsNCT06144164
Breast Cancer, Breast Carcinoma
Basking Ridge, New Jersey, United States
View Trial DetailsNCT07043140
Breast Diseases, Breast Neoplasms
Malatya, Battalgazi, Turkey (Türkiye)
View Trial DetailsNCT07701018
Breast Cancer, Breast Diseases
Kansas City, Missouri, United States
View Trial Details